GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (GREY:IFTBF) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of Jun. 19, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Infant Bacterial Therapeutics AB's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Infant Bacterial Therapeutics AB's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Infant Bacterial Therapeutics AB's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.


Infant Bacterial Therapeutics AB  (GREY:IFTBF) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Infant Bacterial Therapeutics AB EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (GREY:IFTBF) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)
Comparable Companies
OSTO:FLUO OSTO:HNSA OSTO:BINV OSTO:XSPRAY OSTO:EGTX OSTO:VICO OSTO:ONCO OSTO:DMYD B OSTO:CANTA OSTO:XBRANE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
IBT B:Sweden 9IB:Germany
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Website
https://www.ibtherapeutics.com
Infant Bacterial Therapeutics AB is a pharmaceutical company that develops drugs influencing the human infant microbiome, and thereby prevents or treats rare diseases affecting premature infants. It is currently developing its lead drug candidate IBP-9414, to prevent NEC and improve feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants.

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Headlines

No Headlines